Elimination of canrenone in congestive heart failure and chronic liver disease.
The elimination half-life (T1/2) of canrenone, the principal unconjugated metabolite of spironolactone, was 59 h (range 32-105 h) in 5 patients with chronic liver disease and 37 h (range 19-48 h ) in 7 patients withcongestive heart failure. In comparison the T1/2 in normal subjects was 13.5-24 h in previous reports and 20.5 h in the present study, However there was no evidence of greater cumulation of canrenone in the plasma of those patients with a prolonged T1/2.
D000368:Aged; D002192:Canrenone / Q000097:blood*; D002908:Chronic Disease; D003404:Creatinine / Q000097:blood; D005260:Female; D006207:Half-Life; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D008107:Liver Diseases / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011245:Pregnadienes / Q000097:blood*; D012709:Serum Albumin / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use
D011245:Pregnadienes; D012709:Serum Albumin; D013148:Spironolactone; D002192:Canrenone; D003404:Creatinine